Is hormone replacement therapy protective for venous ulcer of the lower limbs?
- 1 May 2001
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 10 (3) , 245-251
- https://doi.org/10.1002/pds.582
Abstract
Purpose Estrogen has been found to increase the risk of deep vein thrombosis (DVT), which is associated with venous ulcers. A matched case–control study was therefore performed to quantify the effect of hormone replacement therapy (HRT) on the occurrence of venous ulcers of the lower limbs. Methods Women presenting to a participating vascular surgery department between January and December 1997 with a first open venous ulcer served as cases. Controls were sampled among women with sub‐acute conditions such as skin problems, cold, headache/migraine, sore throat and mild ear infections, and were matched on referral site and age (±5 years). Subjects were eligible for this study if they were postmenopausal, and excluded if they had non‐palpable pedal pulse or any chronic active diseases. The study consisted of an interviewer‐administered risk factor questionnaire. Conditional multivariate logistic regression analyses were performed adjusting for history of DVT and unbalanced distributions in important covariates. Results Forty‐four cases and 80 matched controls were recruited. The mean age of participants was 64 years. HRT users were significantly thinner 27% with body mass index (BMI = (kg/height (m2)) ≥ 27 vs. 41%, p = 0.04) and less likely to have a history of DVT (12 vs. 33%, p = 0.02) and varicose veins (VV) (52 vs. 69%, p = 0.04) than non‐users. A matched univariate logistic regression analysis was performed to quantify the effect of HRT on venous ulcers and generated an odds ratio (OR) of 0.14 with 95% confidence interval of (0.04, 0.49)95%: adjusting for prior DVT resulted in an OR of 0.29 (0.09, 0.93)95%. When adjusting for BMI, history of VV, exercise, education, and smoking, the OR observed was 0.03 (0.01, 0.13)95%: further adjustment for prior DVT gave an OR estimate of 0.06 (0.01, 0.50)95%CI. Conclusions Our study demonstrates that HRT has a protective effect on the occurrence of venous ulcers of the lower limbs. Adjusting for prior DVT moves the estimate closer to the null. DVT is a strong contraindication for HRT and therefore must be considered in order to eliminate confounding by contraindication. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Health Research and Development Program of Canada
- Fonds de la recherche en santé du Québec
This publication has 7 references indexed in Scilit:
- Assessment of the risk for venous thromboembolism among users of hormone replacement therapy.Drugs & Aging, 1999
- Hormone Replacement Therapy with Estradiol and Risk of Venous ThromboembolismThrombosis and Haemostasis, 1999
- Hormone replacement therapy and risk of venous thromboembolism: population based case-control studyBMJ, 1997
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Prior to Use of Estrogen Replacement Therapy, Are Users Healthier than Nonusers?American Journal of Epidemiology, 1996
- Risk factors for chronic venous insufficiency: A dual case-control studyJournal of Vascular Surgery, 1995
- EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECTEpidemiology, 1995